Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akorn Inc (AKRX) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 2,739,020
  • Shares Outstanding, K 126,030
  • Annual Sales, $ 985,080 K
  • Annual Income, $ 150,800 K
  • 36-Month Beta 1.12
  • Price/Sales 2.46
  • Price/Book 3.40

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.98 +12.51%
on 12/15/16
23.71 -5.19%
on 01/04/17
+2.01 (+9.82%)
since 12/13/16
3-Month
17.61 +27.65%
on 12/07/16
28.37 -20.76%
on 10/14/16
-5.61 (-19.97%)
since 10/13/16
52-Week
17.57 +27.95%
on 03/18/16
35.40 -36.50%
on 08/04/16
-5.34 (-19.19%)
since 01/13/16

Most Recent Stories

More News
Akorn to Present at 35th Annual J.P Morgan Healthcare Conference

Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that Akorn's CEO, Raj Rai, will present at the 35 Annual J.P. Morgan Healthcare Conference.

Biotech Companies Continue Quest for Advanced Drug Developments

Biotech stocks are hoping for some sort of cut in regulations to speed up drug candidate approvals as companies focus on innovative drug advancements despite recent pricing concerns. Biotech stocks with...

Alexion and Viacom tumble, while Chipotle climbs

NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday:

Akorn Announces Completion of FDA Re-inspection of Decatur Facility

Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) conducted a re-inspection of its Decatur, Illinois manufacturing...

Research Reports Initiation on Healthcare Stocks -- Valeant Pharma, Akorn, Universal Health Services, and LifePoint Health

In today's pre-market research, Stock-Callers.com directs investors' attention to the following Healthcare stocks: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Akorn Inc. (NASDAQ: AKRX), Universal...

Akorn Launches Ibuprofen Oral Suspension

Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that it has launched the prescription version of Ibuprofen 100mg/5mL oral suspension in 118mL and 473mL bottles as...

Akorn Invalidates Durezol(R) Patent Via Inter Partes Review Proceeding

Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that on November 22, 2016, the Patent Trial and Appeal Board (PTAB) ruled in favor of Akorn in its inter partes review...

Is Mallinckrodt (MNK) Poised for a Beat in Q4 Earnings?

Mallinckrodt plc (MNK) is set to report fourth-quarter fiscal 2016 results on Nov 29. The company has beaten estimates in each of the last four quarters, with a positive average earnings surprise of 11.9%....

Akorn Down 26.4% Since SmarTrend Downtrend Call (AKRX)

SmarTrend identified a Downtrend for Akorn (NASDAQ:AKRX) on August 16th, 2016 at $30.13. In approximately 3 months, Akorn has returned 26.37% as of today's recent price of $22.18.

Downgrade Alert for Akorn (AKRX)

Akorn (NASDAQ:AKRX) was downgraded from Buy to Underperform at BofA/Merrill today. The stock closed yesterday at $20.26 on volume of 3.5 million shares, above average daily volume of 1.5 million. There...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others. They also market ophthalmic surgical instruments and related products. Customers include physicians, optometrists, wholesalers,...

See More

Support & Resistance

2nd Resistance Point 23.01
1st Resistance Point 22.75
Last Price 22.48
1st Support Level 21.99
2nd Support Level 21.49

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.